PEN - Penumbra, Inc.
收市後：
| 前收市價 | 320.86 |
| 開市 | 318.11 |
| 買盤 | 0.00 x 900 |
| 賣出價 | 0.00 x 4000 |
| 今日波幅 | 318.60 - 323.00 |
| 52 週波幅 | 114.86 - 324.38 |
| 成交量 | |
| 平均成交量 | 349,362 |
| 市值 | 12.311B |
| Beta 值 (5 年，每月) | 0.54 |
| 市盈率 (最近 12 個月) | 2,011.44 |
| 每股盈利 (最近 12 個月) | 0.16 |
| 業績公佈日 | 2023年8月02日 - 2023年8月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 321.44 |
Insider MonkeyShould You Invest in Penumbra (PEN)?
ClearBridge Investments, an investment management company, released its “ClearBridge SMID Cap Growth Strategy” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, the strategy underperformed the Russell 2500 Growth benchmark. On an absolute basis, the strategy gained in six of the 10 sectors it was invested in […]
Insider Monkey12 Stocks To Sell According to Motley Fool
In this article, we will be looking at 12 stocks to sell according to Motley Fool. To skip our detailed analysis of current market dynamics heading into 2023, you can go directly to see the 5 Stocks To Sell According to Motley Fool. Motley Fool Asset Management focuses on high-quality growth companies, and it is constantly […]
Insider Monkey15 Biggest Medical Device Companies in the World
In this article, we will take a look at the 15 biggest medical device companies in the world. If you want to skip our introduction to the industry, then take a look at 5 Biggest Medical Device Companies in the World. The medical device market comprises companies that manufacture equipment used in diagnosing, treating and surveillance […]
BenzingaPenumbra's Lightning Flash Launch Pushed Into Next Year, Trims FY22 Forecasts
Penumbra Inc (NYSE: PEN) posted Q3 FY22 revenue of $213.7 million, +12.4% Y/Y (up 15.1% in constant currency), beating the consensus of $212.28 million. Revenue from sales of vascular products grew 17% (18.8%) to $123.4 million. Revenue from sales of neuro products grew 6.7% (10.5%) to $90.3 million. The gross margin was almost stagnant at 63%. The company reported an adjusted operating income of $7.8 million, down from $8.8 million posted a year ago. The company reported an adjusted EPS of $0.0
BenzingaPenumbra Ramps Up Efforts To Launch Indigo Aspiration System In Japan
Penumbra Inc (NYSE: PEN) and Japan-based medical device manufacturer Asahi Intecc Co will collaborate to introduce Penumbra's Indigo Aspiration System into the Japanese market upon regulatory approval. The Indigo Aspiration System can be used to remove emboli and thrombi from peripheral arterial and venous systems vessels and treat pulmonary embolism. Indigo is a minimally-invasive device that enables blood flow restoration in cases such as acute limb ischemia and venous thrombus. Related: Citin
BenzingaCiting 'Lightning Fast Growth,' Needham Upgrades This Vascular Device Company
Needham upgraded Penumbra Inc (NYSE: PEN) to Buy from Hold, with a price target of $244. The analyst notes that management indicated PEN is seeing stronger growth in 3Q22 due to an improvement in hospital staffing, share gains, or a combination of these. Penumbra recently announced European approval for RED Reperfusion Catheters, which are part of the company's Penumbra System, a fully integrated mechanical aspiration thrombectomy system designed to restore blood flow in acute ischemic stroke pa
- Insider Monkey
12 Best Medical Device Stocks To Buy Now
In this piece, we will take a look at the twelve best medical device stocks to buy now. If you want to skip our introduction to the industry and jump to the top five stocks in this list, then take a look at 5 Best Medical Device Stocks To Buy Now. The outset of the […]
BenzingaWith Sustained Double-Digit Growth Profile, RBC Starts Coverage On This MedTech Stock
RBC Capital Markets initiated coverage on Penumbra Inc (NYSE: PEN) with an Outperform rating and a price target of $195 (59% implied upside). The analysts write that Penumbra is a medical device company operating in attractive, high-growth, under-penetrated neuro and vascular end markets. RBC writes that PEN is investing to position itself for continued growth, but the company is profitable with a clear pathway for expanding margins. Related: Despite Seeing Accelerated 2023 Growth, This Analyst